We are live on !
Find out more
Birchview Capital Portfolio holdings
AUM
$214M
Turnover
33.33%
1-Year Est. Return
185.33%
This Fund
S&P 500
This Quarter Est. Return
+47.89%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$214M
AUM Growth
+$38.2M
(+22%)
Cap. Flow
-$12.5M
Cap. Flow % of AUM
Cap. Flow %
-5.84%
Top 10 Holdings %
Top 10 Hldgs %
59.94%
Holding
87
New
14
Increased
17
Reduced
22
Closed
15
Avg Time Held
2.3
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$3.66M |
| 2 |
Vir Biotechnology
VIR
|
+$2.09M |
| 3 |
Abivax
ABVX
|
+$1.92M |
| 4 |
Halozyme
HALO
|
+$1.58M |
| 5 |
BioAge Labs
BIOA
|
+$1.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KLA
KLAC
|
+$4.04M |
| 2 |
Compass Pathways
CMPS
|
+$3.5M |
| 3 |
Structure Therapeutics
GPCR
|
+$3.36M |
| 4 |
Ocular Therapeutix
OCUL
|
+$2.71M |
| 5 |
NovoCure
NVCR
|
+$2.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.39% |
| 2 | Technology | 32.27% |
| 3 | Energy | 3.51% |
| 4 | Materials | 0.53% |
| 5 | Financials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
CAMP4 Therapeutics
CAMP
$213M
| $524K | 0.25% |
+120,000
| New | +$517K |
2026 Q2
0 quarters
|
|
52
Savara
SVRA
$933M
| $493K | 0.23% |
+80,000
| New | +$429K |
2026 Q2
0 quarters
|
|
53
Candel Therapeutics
CADL
$641M
| $492K | 0.23% |
47,756
-12,244
| -20% | -$92.5K |
2024 Q4
6 quarters
|
|
54
Altimmune
ALT
$422M
| $464K | 0.22% |
+152,681
| New | +$456K |
2026 Q2
0 quarters
|
|
|
55
Compass Pathways
CMPS
$1.61B
| $424K | 0.2% |
30,000
-345,000
| -92% | -$3.5M |
2026 Q1
1 quarter
|
|
56
Karyopharm Therapeutics
KPTI
$12.4M
| $420K | 0.2% |
42,952
-41,000
| -49% | -$356K |
2026 Q1
1 quarter
|
|
57
Cullinan Oncology
CGEM
$960M
| $364K | 0.17% |
20,000
| – | – |
2021 Q1
21 quarters
|
|
58
Trinity Capital Inc
TRIN
$1.55B
| $358K | 0.17% |
20,000
| – | – |
2025 Q4
2 quarters
|
|
59
Capricor Therapeutics
CAPR
$356M
| $346K | 0.16% |
+14,352
| New | +$435K |
2026 Q2
0 quarters
|
|
60
Castle Biosciences
CSTL
$1.01B
| $310K | 0.14% |
12,984
+84
| +0.7% | +$1.87K |
2023 Q4
10 quarters
|
|
61
Invivyd
IVVD
$180M
| $299K | 0.14% |
+342,275
| New | +$429K |
2026 Q2
0 quarters
|
|
62
Grace Therapeutics
GRCE
$40.4M
| $272K | 0.13% |
120,000
+70,000
| +140% | +$194K |
2026 Q1
1 quarter
|
|
63
Kayne Anderson BDC
KBDC
$843M
| $271K | 0.13% |
20,000
| – | – |
2025 Q4
2 quarters
|
|
64
Voyager Therapeutics
VYGR
$115M
| $263K | 0.12% |
75,147
+229
| +0.3% | +$868 |
2025 Q3
3 quarters
|
|
65
Pulmonx
LUNG
$80.7M
| $261K | 0.12% |
200,543
-49,678
| -20% | -$68.4K |
2025 Q4
2 quarters
|
|
|
66
Ocular Therapeutix
OCUL
$1.45B
| $203K | 0.09% |
20,655
-299,345
| -94% | -$2.71M |
2026 Q1
1 quarter
|
|
67
Kyntra Bio
KYNB
$21.1M
| $170K | 0.08% |
22,566
| – | – |
2026 Q1
1 quarter
|
|
68
Elutia
ELUT
$38.2M
| $162K | 0.08% |
165,094
| – | – |
2021 Q2
20 quarters
|
|
69
Quoin Pharmaceuticals
QNRX
$19.3M
| $96.8K | 0.05% |
20,000
| – | – |
2026 Q1
1 quarter
|
|
70
Lipocine
LPCN
$12M
| $42.8K | 0.02% |
16,712
-95,074
| -85% | -$229K |
2026 Q1
1 quarter
|
|
71
DocGo
DCGO
$26.7M
| $20.2K | 0.01% |
39,062
-511
| -1% | -$305 |
2021 Q4
18 quarters
|
|
72
Gossamer Bio
GOSS
$57.9M
| $2.99K | ﹤0.01% |
227
| – | – |
2021 Q3
19 quarters
|
|
73
DELISTED
Apogee Therapeutics
APGE
| – | – |
-9,000
| Closed | -$758K | – |
|
74
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-14,000
| Closed | -$563K | – |
|
75
enGene Therapeutics
ENGN
$106M
| – | – |
-250,000
| Closed | -$1.7M | – |
|
Similar funds
Birchview Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Birchview Capital held 87 positions worth $214M, up 22% from $176M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Birchview Capital withdrew a net $12.5M in Q2 2026, closing 15 positions and reducing 22 holdings. Its most notable exit was NovoCure, an estimated $2.21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Technology and Energy.
Against the trend, Birchview Capital opened a new position in Vir Biotechnology worth $2.24M.
- Birchview Capital's largest Q2 2026 buy was Vir Biotechnology: 220,000 shares worth $2.24M.
- Birchview Capital added most to Nektar Therapeutics in Q2 2026, an estimated $3.66M increase.
- Birchview Capital's biggest Q2 2026 reduction was KLA, cutting an estimated $4.04M.
- Birchview Capital fully exited NovoCure in Q2 2026, selling an estimated $2.21M.
- Birchview Capital's ten largest holdings make up 60% of its $214M portfolio in Q2 2026.
- Birchview Capital opened 14 new positions and closed 15 in Q2 2026.
- Birchview Capital's portfolio value rose 22% quarter-over-quarter to $214M.
Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.